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Evidence has accrued in the last decade that chemotherapy is an
effective treatment modality in the management of patients with
advanced non-small cell lung cancer (NSCLC) (Non-small Cell
Lung Cancer Collaborative Group, 1995). Clinical benefit is
evidenced from phase III randomized trials showing survival,
symptomatic and quality of life benefits (Non-small Cell Lung
Cancer Collaborative Group, 1995; Cullen et al, 1999; Anderson
et al, 2000). The optimal chemotherapeutic regimen and the
magnitude of benefit in day-to-day clinical practice however
remains controversial. 
For the large number of patients diagnosed with advanced
NSCLC, improvements in systemic therapy offer the only realistic
possibility of increasing survival, and probably also local control,
which even with surgical intervention, with or without radiation
therapy, in stage IIIA disease remains poor (Rosell et al, 1994; Roth
et al, 1994). The problem is that to date relatively few active systemic
agents have been identified in this context. The survival benefit with
chemotherapy demonstrated by meta-analysis in advanced NSCLC
was obtained primarily with cisplatin, often in combination with ifos-
famide, vindesine and mitomycin C (MMC). The NSCLCCG meta-
analysis showed a 27% reduction in the risk of death equivalent to an
improvement in survival of 10% at 1 year and an increase in median
survival of 6 weeks with cisplatin-based chemotherapy. 
Although widely incorporated into combination doublet therapies
most commonly with cisplatin or carboplatin, the extent of improve-
ment in outcome with the newer second generation drugs introduced
in the last decade including gemcitabine, paclitaxel, docetaxel,
vinorelbine and irinotecan has yet to be clearly defined. Early opti-
mism with consistently high response rates for each agent and in
combination (Table 1) has not been translated into dramatic survival
benefits in advanced NSCLC. In spite of large studies neither has
any new combination clearly established itself as a consistently
superior reference therapy (Bonomi et al, 2000). Differences in clin-
ical trial populations with varying proportions of locally advanced
(stage IIIB) and metastatic (stage IV) NSCLC seems to account for
more variation in survival as a principal outcome measure than
differences in dosage and/or drug schedules. 
During the 1970s single agents with low activity were combined
in the hope of attaining a higher response rate and increased
survival. Initial enthusiasm for these drug combinations was
tempered by an inability to demonstrate a survival benefit in phase
III randomized trials. Indeed no randomized trial of first genera-
tion agents has in isolation shown a survival advantage for a
combination over single agent cisplatin, although response rates
may be increased by combination therapy. 
In this issue Sculier and colleagues have performed a meta-
analysis of the role of Mitomycin C (MMC) (Sculier et al, 2001).
At present combinations of cisplatin and MMC with either
vinblastine or ifosfamide are popular schedules particularly in the
UK. Sculier et al report that MMC is associated with a 25% objec-
tive response rate when administered as single-agent first-line
chemotherapy in advanced NSCLC, but does not improve survival
when used in combination with other first generation active cyto-
static agents like cisplatin, vindesine and vinblastine. When a large
study using a comparison of a probably inadequate dose of vinde-
sine (3 mg/m2 every 2 weeks or 3 mg/m2 weekly for 5 weeks
followed by a dose every 2 weeks) is excluded (Luedke et al,
1990) neither does the meta-analysis indicate an improvement in
response rate. Sculier et al conclude that MMC should not be used
anymore in combination with the first generation active cytostatic
agents as it does not improve survival in this setting. They suggest
that the role of MMC as salvage chemotherapy or in combination
with the second generation active drugs requires further study,
owing to the paucity of studies available for analysis. 
Inevitably the new agents will shortly be submitted to meta-
analysis for possible survival benefits over competitors. Perhaps
the major message from this work should be first, a concentration
of further discussion about what the relevant end-points are for
study with existing agents. Secondly the data should encourage
consistency of clinical trial design, particularly in terms of
eligibility criteria, and data reporting in NSCLC. 
Editorial 
Meta-analysis of single agents in the chemotherapy of
NSCLC: what do we want to know? 
A Bahl and S Falk 
Bristol Haematology and Oncology Centre, Horfield Rd, Bristol BS2 8ED, UK 
1143
Correspondence to: S Falk 
Table 1 Second generation agents in NSCLC 
Drug Range of overall  Mean overall
response rate (%)  response rate (%)
Gencitabine 19–23 22 
Irinotecan 0–34 26 
Vinorelbine 8–36 22 
Paclitaxel 22–42 28 
Docetaxel 23–39 31 
Some second generation agents in combination in NSCLC 
Drugs Range of overall response rate(%) 
Gencitabine + Cisplatin 58–60 
Paclitaxel + Carboplatin 27–63 
Cisplatin + Irinotecan 49–54 
Cisplatin + Vinorelbine 26–52 
Paclitaxel + Cisplatin 31–47 
Derived and adapted from Bunn, 1996. 
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tant primary end-point of cancer therapies, when given with
curative intent, other end-points become of increasing signifi-
cance when there is likely to be no major difference in survival.
When treatment cannot cure and survival time is likely to be
short as is common in NSCLC the physical, emotional, philo-
sophical and spiritual dimensions of the remaining life require
the greatest consideration and sensitivity of assessment. For
example, symptom control, quality of life or toxicity, conve-
nience and financial costs of treatment could not be meaningfully
evaluated in this meta-analysis by Sculier et al and it is important
to consider these before totally discounting the role of MMC in
advanced NSCLC. This realization about the meaningful end-
points to be studied becomes even more apparent by reviewing
large recent randomized trials performed by ECOG and the
EORTC (Giaccone et al, 1998; Bonomi et al, 2000). These trials
did not show any significant survival advantage between newer
agents like paclitaxel or gemcitabine in combination with
cisplatin when compared to the older chemotherapeutic regimes.
Survival benefit has however been reported in studies using the
combination of cisplatin and vinorelbine (Le Chevalier et al,
1996; Wozniak et al, 2000). Some treatment combinations such
as gemcitabine and cisplatin yield equivalent or higher response
rates and in some studies prolong time to disease progression
(Evans et al, 1999). Hence it is important to consider all relevant
end-points before discounting a drug purely on its inability to
improve survival alone. 
Health economic assessments of chemotherapy for advanced
NSCLC have been conducted in the Canadian and UK healthcare
systems. These have shown an economic advantage for patients
treated with chemotherapy over the cost of patients who received
supportive care alone (Jaakkimainen et al, 1990; Anderson et al,
2000). More recent work has shown significant differences in the
costs associated with different regimens (Berthelot et al, 2000).
The application of this analysis to other healthcare systems is
uncertain but nonetheless cannot be ignored. 
The symptomatic benefit associated with chemotherapy has
been emphasized in several studies with overall relief of symp-
toms in greater than two-thirds of patients (Ellis et al, 1995).
Quality of life should be an important component of clinical
studies in advanced NSCLC and along with health economics
would be helpful in deciding between different treatment options.
Quality of life (QoL) in particular whilst mandatory in all cancer
trials requires further assessment as to how much the results
obtained by current techniques have actually influenced practice.
Simplification of QoL techniques to improve clinical utility are to
be encouraged. Any QoL instrument should be simple to
administer and easy to explain, complete and analyse (Donnelly
and Walsh, 1996). 
This meta-analysis, which although it does not show an
improvement in outcome in terms of survival as a primary end-
point, should be viewed in the context of how we may better
expand our knowledge base of new agents by phase III study.
Importantly we should consider carefully what we want to achieve
for our patients by different combinations of therapies. We would
like to propose for initial discussion that 
1. Eligibility for palliative studies should be unified to stage IV
disease and IIIB with pleural effusion, i.e. patients for whom
radical local therapy in particular with radiotherapy would not
be contemplated. 
2. There is consistency in reporting of 1-year survival as a
primary end-point. 
3. Quality of life scores should be performed using a straightfor-
ward validated instrument. 
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